VBS

Vectus Biosystems Limited

1 day chart

About VBS

Vectus Biosystems Limited (VBS) is a public company based at Julius Avenue, North Ryde, Sydney, Australia. Vectus has developed potentially novel treatments for fibrosis and high blood pressure, which include treatment for three of the largest diseases in the fibrotic franchise, namely heart, kidney and liver disease. The Company has also developed technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Buy Australian shares starting with VBS. Invest today with a CHESS-sponsored investing platform!

Sector

Health Care

CEO

Industry

Biotechnology

Website

vectusbiosystems.com.au

Market Capitalisation

$17M

Price-earnings ratio

-4.38

Dividend yield

NaN%

High today

$0.32

Low today

$0.32

Open price

$0.32

52-week high

$0.93

52-week low

$0.30

Announcements

VBS FAQs

Can I buy VBS shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?

Yes, the Stake platform allows you to buy VBS shares and over 8,000 stocks and ETFs across the ASX and Wall St.

How much is one share of Vectus Biosystems Limited?

One share of Vectus Biosystems Limited is valued at $0.32.

What is the ticker symbol for Vectus Biosystems Limited?

The ticker symbol for Vectus Biosystems Limited is VBS.

How do I buy VBS shares in Australia?

To buy VBS stocks in Australia you'll need to open an account with an investing platform like Stake.
To do so follow these steps:

Sign up in minutes, all you need is some I.D.
Choose Stake AUS
Deposit directly into your Stake wallet and you're ready to invest in VBS

What is the 52-week high for Vectus Biosystems Limited stock?

The Vectus Biosystems Limited 52-week high stock price is $0.93.

What is the 52-week low for Vectus Biosystems Limited stock?

The Vectus Biosystems Limited 52-week low stock price is $0.30.

What is the market capitalisation of Vectus Biosystems Limited VBS?

As of 05/12/2023 Vectus Biosystems Limited has a market cap of $17M.

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.